Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
21.71
+0.51 (2.41%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Stevanato Group Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,225 | 1,186 | 1,104 | 1,085 | 983.68 | 843.92 |
Revenue Growth | 7.00% | 7.45% | 1.72% | 10.34% | 16.56% | 27.47% |
Gross Profit Gross Profit Growth | 360.21 | 346.2 | 305.44 | 339.89 | 319.8 | 265.41 |
Operating Income Operating Income Growth | 216.55 | 203.84 | 167.59 | 200.45 | 192.31 | 162.2 |
Net Income Net Income Growth | 134.61 | 139.84 | 117.78 | 145.63 | 142.85 | 134.32 |
Earnings Per Share EPS Growth | 0.49 | 0.51 | 0.43 | 0.55 | 0.54 | 0.53 |
EPS Growth | 0.17% | 18.60% | -21.77% | 1.85% | 1.82% | 62.35% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Biopharmaceutical and Diagnostic Solutions Biopharmaceutical and Diagnostic Solutions Growth | 1,089 | 1,038 | 933.74 | 879.29 | 799.65 | 694.04 |
Engineering Engineering Growth | 136.25 | 148.11 | 170.29 | 206.07 | 184.03 | 149.88 |
Revenue (Total) Revenue (Total) Growth | 1,225 | 1,186 | 1,104 | 1,085 | 983.68 | 843.92 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 79.14 | 132.38 | 98.98 | 72.18 | 261.49 | 438.21 |
Total Debt Total Debt Growth | 445.3 | 469.71 | 429.96 | 397.08 | 219.16 | 248.49 |
Net Cash (Debt) Net Cash Growth | -366.16 | -337.33 | -330.98 | -324.9 | 42.33 | 189.72 |
Net Cash Growth | - | - | - | - | -77.69% | - |
Net Cash Per Share Net Cash Per Share Growth | -1.34 | -1.24 | -1.22 | -1.23 | 0.16 | 0.75 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 248.68 | 286.08 | 155.78 | 105.21 | 103.31 | 133.34 |
Capital Expenditures CapEx Growth | -259.66 | -263.76 | -302.6 | -433.23 | -235.03 | -107.69 |
Free Cash Flow Free Cash Flow Growth | -10.98 | 22.32 | -146.82 | -328.02 | -131.72 | 25.65 |
Free Cash Flow Growth | - | - | - | - | - | -61.20% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 29.40% | 29.18% | 27.66% | 31.32% | 32.51% | 31.45% |
Operating Margin | 17.67% | 17.18% | 15.18% | 18.47% | 19.55% | 19.22% |
Pretax Margin | 15.69% | 15.94% | 14.52% | 17.46% | 19.08% | 19.63% |
Profit Margin | 10.99% | 11.79% | 10.67% | 13.42% | 14.52% | 15.92% |
FCF Margin | -0.90% | 1.88% | -13.30% | -30.22% | -13.39% | 3.04% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.063 | - | 0.054 | 0.053 | 0.054 | 0.051 |
Dividend Per Share Growth | 1.13% | - | 1.89% | -1.85% | 5.88% | -99.98% |
Dividend Yield | 0.29% | - | 0.26% | 0.22% | 0.33% | 0.26% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.78 | 33.46 | 48.77 | 45.14 | 31.16 | 38.90 |
Forward PE | 28.83 | 29.61 | 38.13 | 39.60 | 32.31 | 45.63 |
P/FCF Ratio | - | 209.59 | - | - | - | 203.75 |
PS Ratio | 4.24 | 3.94 | 5.20 | 6.06 | 4.53 | 6.19 |